ABSK043 + firmonertinib

ABSK043 + firmonertinib is a combination therapy under investigation for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. ABSK043 is an orally bioavailable, highly selective, and potent small molecule inhibitor of programmed death-ligand 1 (PD-L1), developed by Abbisko Therapeutics. It works by selectively binding to PD-L1, inducing its internalization from the cell surface and inhibiting the interaction between PD-L1 and PD-1, thereby alleviating immune suppression and enhancing T-cell activation. Firmonertinib (also known as furmonertinib) is a third-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor developed by Allist Pharmaceuticals, targeting EGFR mutations commonly found in NSCLC. The combination aims to improve anti-tumor efficacy through dual inhibition of immune checkpoint pathways and oncogenic signaling[2][6][7].

Brand names

furmonertinib

Other names

ABSK 043ABSK043ABSK-043Furmonertinib